User login
Cardiovascular disease in oncology
Article Type
Changed
Fri, 01/04/2019 - 11:11
Display Headline
Cardiovascular disease in oncology
In the first quarter of 2015, a number of papers that addressed cardiovascular issues in oncology were published. These included studies of the cardiovascular toxicity of cancer therapy, treatment guidelines from the American Society of Clinical Oncology (ASCO) for venous thromboembolism prophylaxis (VTE), and the prognostic significance of superficial vein thrombosis.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(6)
Page Number
231-234
Legacy Keywords
cardiovascular disease, CVD, cardiovascular toxicity, venous thromboembolism, VTE, superficial vein thrombosis, SVT, prostate cancer, cerebral microbleeds, CMBs, whitematter lesions, WMLs, vascular adverse events, VAEs, nilotinib, ponatinib, bosutinib, dasatinib
Sections
Article PDF
Article PDF
In the first quarter of 2015, a number of papers that addressed cardiovascular issues in oncology were published. These included studies of the cardiovascular toxicity of cancer therapy, treatment guidelines from the American Society of Clinical Oncology (ASCO) for venous thromboembolism prophylaxis (VTE), and the prognostic significance of superficial vein thrombosis.
Click on the PDF icon at the top of this introduction to read the full article.
In the first quarter of 2015, a number of papers that addressed cardiovascular issues in oncology were published. These included studies of the cardiovascular toxicity of cancer therapy, treatment guidelines from the American Society of Clinical Oncology (ASCO) for venous thromboembolism prophylaxis (VTE), and the prognostic significance of superficial vein thrombosis.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 13(6)
Issue
The Journal of Community and Supportive Oncology - 13(6)
Page Number
231-234
Page Number
231-234
Article Type
Display Headline
Cardiovascular disease in oncology
Display Headline
Cardiovascular disease in oncology
Legacy Keywords
cardiovascular disease, CVD, cardiovascular toxicity, venous thromboembolism, VTE, superficial vein thrombosis, SVT, prostate cancer, cerebral microbleeds, CMBs, whitematter lesions, WMLs, vascular adverse events, VAEs, nilotinib, ponatinib, bosutinib, dasatinib
Legacy Keywords
cardiovascular disease, CVD, cardiovascular toxicity, venous thromboembolism, VTE, superficial vein thrombosis, SVT, prostate cancer, cerebral microbleeds, CMBs, whitematter lesions, WMLs, vascular adverse events, VAEs, nilotinib, ponatinib, bosutinib, dasatinib
Sections
Citation Override
JCSO 2015;13:231-234
Disallow All Ads
Alternative CME
Article PDF Media
Document
New approvals, genetic testing, maintenance therapy, and DFS in ovarian cancer
Article Type
Changed
Fri, 01/04/2019 - 11:10
Display Headline
New approvals, genetic testing, maintenance therapy, and DFS in ovarian cancer
Genetic testing in women with ovarian cancer1
Recent study findings have indicated that women with ovarian cancer may have BRCA1 or BRCA2 mutations despite a negative family history, and current NCCN (National Comprehensive Cancer Network) guidelines endorse genetic testing for all women with epithelial cancer of the ovary. Despite this, recent reports indicate that most women with ovarian cancer are not being tested, particularly those who are elderly or without a family history. In this paper by Daniels and colleagues, the investigators examined targeted versus universal genetic testing to see if the use of a well-regarded risk model (BRCAPRO) based on personal and family history could discriminate among patients with high-grade serous ovarian cancer. Targeted genetic testing in this group might help lower costs and encourage testing for those women who actually have a significant chance of carrying a deleterious gene mutation.
Recent study findings have indicated that women with ovarian cancer may have BRCA1 or BRCA2 mutations despite a negative family history, and current NCCN (National Comprehensive Cancer Network) guidelines endorse genetic testing for all women with epithelial cancer of the ovary. Despite this, recent reports indicate that most women with ovarian cancer are not being tested, particularly those who are elderly or without a family history. In this paper by Daniels and colleagues, the investigators examined targeted versus universal genetic testing to see if the use of a well-regarded risk model (BRCAPRO) based on personal and family history could discriminate among patients with high-grade serous ovarian cancer. Targeted genetic testing in this group might help lower costs and encourage testing for those women who actually have a significant chance of carrying a deleterious gene mutation.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(3)
Page Number
122-124
Legacy Keywords
ovarian cancer, BRCA1, BRCA2, bevacizumab, pazopanib, olaparib, end-of-life care
Sections
Article PDF
Article PDF
Genetic testing in women with ovarian cancer1
Recent study findings have indicated that women with ovarian cancer may have BRCA1 or BRCA2 mutations despite a negative family history, and current NCCN (National Comprehensive Cancer Network) guidelines endorse genetic testing for all women with epithelial cancer of the ovary. Despite this, recent reports indicate that most women with ovarian cancer are not being tested, particularly those who are elderly or without a family history. In this paper by Daniels and colleagues, the investigators examined targeted versus universal genetic testing to see if the use of a well-regarded risk model (BRCAPRO) based on personal and family history could discriminate among patients with high-grade serous ovarian cancer. Targeted genetic testing in this group might help lower costs and encourage testing for those women who actually have a significant chance of carrying a deleterious gene mutation.
Recent study findings have indicated that women with ovarian cancer may have BRCA1 or BRCA2 mutations despite a negative family history, and current NCCN (National Comprehensive Cancer Network) guidelines endorse genetic testing for all women with epithelial cancer of the ovary. Despite this, recent reports indicate that most women with ovarian cancer are not being tested, particularly those who are elderly or without a family history. In this paper by Daniels and colleagues, the investigators examined targeted versus universal genetic testing to see if the use of a well-regarded risk model (BRCAPRO) based on personal and family history could discriminate among patients with high-grade serous ovarian cancer. Targeted genetic testing in this group might help lower costs and encourage testing for those women who actually have a significant chance of carrying a deleterious gene mutation.
Click on the PDF icon at the top of this introduction to read the full article.
Genetic testing in women with ovarian cancer1
Recent study findings have indicated that women with ovarian cancer may have BRCA1 or BRCA2 mutations despite a negative family history, and current NCCN (National Comprehensive Cancer Network) guidelines endorse genetic testing for all women with epithelial cancer of the ovary. Despite this, recent reports indicate that most women with ovarian cancer are not being tested, particularly those who are elderly or without a family history. In this paper by Daniels and colleagues, the investigators examined targeted versus universal genetic testing to see if the use of a well-regarded risk model (BRCAPRO) based on personal and family history could discriminate among patients with high-grade serous ovarian cancer. Targeted genetic testing in this group might help lower costs and encourage testing for those women who actually have a significant chance of carrying a deleterious gene mutation.
Recent study findings have indicated that women with ovarian cancer may have BRCA1 or BRCA2 mutations despite a negative family history, and current NCCN (National Comprehensive Cancer Network) guidelines endorse genetic testing for all women with epithelial cancer of the ovary. Despite this, recent reports indicate that most women with ovarian cancer are not being tested, particularly those who are elderly or without a family history. In this paper by Daniels and colleagues, the investigators examined targeted versus universal genetic testing to see if the use of a well-regarded risk model (BRCAPRO) based on personal and family history could discriminate among patients with high-grade serous ovarian cancer. Targeted genetic testing in this group might help lower costs and encourage testing for those women who actually have a significant chance of carrying a deleterious gene mutation.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 13(3)
Issue
The Journal of Community and Supportive Oncology - 13(3)
Page Number
122-124
Page Number
122-124
Article Type
Display Headline
New approvals, genetic testing, maintenance therapy, and DFS in ovarian cancer
Display Headline
New approvals, genetic testing, maintenance therapy, and DFS in ovarian cancer
Legacy Keywords
ovarian cancer, BRCA1, BRCA2, bevacizumab, pazopanib, olaparib, end-of-life care
Legacy Keywords
ovarian cancer, BRCA1, BRCA2, bevacizumab, pazopanib, olaparib, end-of-life care
Sections
Citation Override
JCSO 2015;13:122-124
Disallow All Ads
Alternative CME
Article PDF Media
Document
Update on therapies for lymphoproliferative disorders
Article Type
Changed
Fri, 01/04/2019 - 11:10
Display Headline
Update on therapies for lymphoproliferative disorders
Diabetes mellitus as a late effect of the treatment of Hodgkin lymphoma.1
Two recent follow-up studies of childhood cancer patients who had been treated with abdominal radiation revealed an increased risk of diabetes mellitus (DM) in the survivors. In the past, many patients with a diagnosis of Hodgkin lymphoma (HL) were also treated with infradiaphragmatic radiation. The para-aortic and splenic fields used for this treatment encompasses most of the pancreas, including the tail. Since diabetes is a risk factor for cardiovascular disease, it is conceivable that an increase in diabetes in survivors of HL might contribute to their increased risk of cardiovascular disease. In this recent study of adults, the results of the treatment of 2,352 Dutch 5-year survivors of HL treatment who were younger than 51 years at the time of diagnosis were analyzed. Detailed records of their treatment and late effects of treatment were obtained, including information about DM, hypertension, hypercholesterolemia, smoking, and obesity. Radiation dose to the pancreas was estimated.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(1)
Page Number
34-36
Legacy Keywords
Hodgkin lymphoma, RESORT trial, lymphoma, lymphocytic leukemia
Sections
Article PDF
Article PDF
Diabetes mellitus as a late effect of the treatment of Hodgkin lymphoma.1
Two recent follow-up studies of childhood cancer patients who had been treated with abdominal radiation revealed an increased risk of diabetes mellitus (DM) in the survivors. In the past, many patients with a diagnosis of Hodgkin lymphoma (HL) were also treated with infradiaphragmatic radiation. The para-aortic and splenic fields used for this treatment encompasses most of the pancreas, including the tail. Since diabetes is a risk factor for cardiovascular disease, it is conceivable that an increase in diabetes in survivors of HL might contribute to their increased risk of cardiovascular disease. In this recent study of adults, the results of the treatment of 2,352 Dutch 5-year survivors of HL treatment who were younger than 51 years at the time of diagnosis were analyzed. Detailed records of their treatment and late effects of treatment were obtained, including information about DM, hypertension, hypercholesterolemia, smoking, and obesity. Radiation dose to the pancreas was estimated.
Click on the PDF icon at the top of this introduction to read the full article.
Diabetes mellitus as a late effect of the treatment of Hodgkin lymphoma.1
Two recent follow-up studies of childhood cancer patients who had been treated with abdominal radiation revealed an increased risk of diabetes mellitus (DM) in the survivors. In the past, many patients with a diagnosis of Hodgkin lymphoma (HL) were also treated with infradiaphragmatic radiation. The para-aortic and splenic fields used for this treatment encompasses most of the pancreas, including the tail. Since diabetes is a risk factor for cardiovascular disease, it is conceivable that an increase in diabetes in survivors of HL might contribute to their increased risk of cardiovascular disease. In this recent study of adults, the results of the treatment of 2,352 Dutch 5-year survivors of HL treatment who were younger than 51 years at the time of diagnosis were analyzed. Detailed records of their treatment and late effects of treatment were obtained, including information about DM, hypertension, hypercholesterolemia, smoking, and obesity. Radiation dose to the pancreas was estimated.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 13(1)
Issue
The Journal of Community and Supportive Oncology - 13(1)
Page Number
34-36
Page Number
34-36
Article Type
Display Headline
Update on therapies for lymphoproliferative disorders
Display Headline
Update on therapies for lymphoproliferative disorders
Legacy Keywords
Hodgkin lymphoma, RESORT trial, lymphoma, lymphocytic leukemia
Legacy Keywords
Hodgkin lymphoma, RESORT trial, lymphoma, lymphocytic leukemia
Sections
Citation Override
JCSO 2015;13:34-36
Disallow All Ads
Alternative CME
Article PDF Media
Document
A round-up of ASCO’s 2013-2014 guideline releases, updates, and endorsements
Article Type
Changed
Thu, 12/15/2022 - 18:07
Display Headline
A round-up of ASCO’s 2013-2014 guideline releases, updates, and endorsements
During the past year, the American Society of Clinical Oncology (ASCO) has published 7 special articles that create, update, or endorse clinical practice guidelines. All 7 articles are the subject of this month’s review.
1. Follow-up care, surveillance, and secondary prevention measures for survivors of colorectal cancer1,2
Since 2006, ASCO has adopted a policy of endorsing clinical practice guidelines developed by others in order to increase the number of such guidelines available for ASCO membership. Recently, the society endorsed the guidelines for colon cancer follow-up created by the Cancer Care Ontario (CCO). These guidelines include surveillance recommendations that are very similar to the 2005 ASCO guidelines and the current NCCN guidelines, with a few minor differences. However, unlike NCCN and previous ASCO guidelines, the current guidelines include statements about secondary prevention, written survivorship plans for the patient’s other providers, and the futility of surveillance tests in patients who are not candidates for surgery or systemic therapy due to comorbid disease.
1. Follow-up care, surveillance, and secondary prevention measures for survivors of colorectal cancer1,2
Since 2006, ASCO has adopted a policy of endorsing clinical practice guidelines developed by others in order to increase the number of such guidelines available for ASCO membership. Recently, the society endorsed the guidelines for colon cancer follow-up created by the Cancer Care Ontario (CCO). These guidelines include surveillance recommendations that are very similar to the 2005 ASCO guidelines and the current NCCN guidelines, with a few minor differences. However, unlike NCCN and previous ASCO guidelines, the current guidelines include statements about secondary prevention, written survivorship plans for the patient’s other providers, and the futility of surveillance tests in patients who are not candidates for surgery or systemic therapy due to comorbid disease.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 12(11)
Page Number
421-424
Legacy Keywords
colorectal cancer, breast cancer, sentinel lymph node biopsy, breast-conserving surgery, whole-breast irradiation, peripheral neuropathy
Sections
Article PDF
Article PDF
During the past year, the American Society of Clinical Oncology (ASCO) has published 7 special articles that create, update, or endorse clinical practice guidelines. All 7 articles are the subject of this month’s review.
1. Follow-up care, surveillance, and secondary prevention measures for survivors of colorectal cancer1,2
Since 2006, ASCO has adopted a policy of endorsing clinical practice guidelines developed by others in order to increase the number of such guidelines available for ASCO membership. Recently, the society endorsed the guidelines for colon cancer follow-up created by the Cancer Care Ontario (CCO). These guidelines include surveillance recommendations that are very similar to the 2005 ASCO guidelines and the current NCCN guidelines, with a few minor differences. However, unlike NCCN and previous ASCO guidelines, the current guidelines include statements about secondary prevention, written survivorship plans for the patient’s other providers, and the futility of surveillance tests in patients who are not candidates for surgery or systemic therapy due to comorbid disease.
1. Follow-up care, surveillance, and secondary prevention measures for survivors of colorectal cancer1,2
Since 2006, ASCO has adopted a policy of endorsing clinical practice guidelines developed by others in order to increase the number of such guidelines available for ASCO membership. Recently, the society endorsed the guidelines for colon cancer follow-up created by the Cancer Care Ontario (CCO). These guidelines include surveillance recommendations that are very similar to the 2005 ASCO guidelines and the current NCCN guidelines, with a few minor differences. However, unlike NCCN and previous ASCO guidelines, the current guidelines include statements about secondary prevention, written survivorship plans for the patient’s other providers, and the futility of surveillance tests in patients who are not candidates for surgery or systemic therapy due to comorbid disease.
Click on the PDF icon at the top of this introduction to read the full article.
During the past year, the American Society of Clinical Oncology (ASCO) has published 7 special articles that create, update, or endorse clinical practice guidelines. All 7 articles are the subject of this month’s review.
1. Follow-up care, surveillance, and secondary prevention measures for survivors of colorectal cancer1,2
Since 2006, ASCO has adopted a policy of endorsing clinical practice guidelines developed by others in order to increase the number of such guidelines available for ASCO membership. Recently, the society endorsed the guidelines for colon cancer follow-up created by the Cancer Care Ontario (CCO). These guidelines include surveillance recommendations that are very similar to the 2005 ASCO guidelines and the current NCCN guidelines, with a few minor differences. However, unlike NCCN and previous ASCO guidelines, the current guidelines include statements about secondary prevention, written survivorship plans for the patient’s other providers, and the futility of surveillance tests in patients who are not candidates for surgery or systemic therapy due to comorbid disease.
1. Follow-up care, surveillance, and secondary prevention measures for survivors of colorectal cancer1,2
Since 2006, ASCO has adopted a policy of endorsing clinical practice guidelines developed by others in order to increase the number of such guidelines available for ASCO membership. Recently, the society endorsed the guidelines for colon cancer follow-up created by the Cancer Care Ontario (CCO). These guidelines include surveillance recommendations that are very similar to the 2005 ASCO guidelines and the current NCCN guidelines, with a few minor differences. However, unlike NCCN and previous ASCO guidelines, the current guidelines include statements about secondary prevention, written survivorship plans for the patient’s other providers, and the futility of surveillance tests in patients who are not candidates for surgery or systemic therapy due to comorbid disease.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 12(11)
Issue
The Journal of Community and Supportive Oncology - 12(11)
Page Number
421-424
Page Number
421-424
Article Type
Display Headline
A round-up of ASCO’s 2013-2014 guideline releases, updates, and endorsements
Display Headline
A round-up of ASCO’s 2013-2014 guideline releases, updates, and endorsements
Legacy Keywords
colorectal cancer, breast cancer, sentinel lymph node biopsy, breast-conserving surgery, whole-breast irradiation, peripheral neuropathy
Legacy Keywords
colorectal cancer, breast cancer, sentinel lymph node biopsy, breast-conserving surgery, whole-breast irradiation, peripheral neuropathy
Sections
Citation Override
JCSO 2014;12:421-424
Disallow All Ads
Alternative CME
Article PDF Media
Document
To screen or not to screen: lung and breast cancer
Article Type
Changed
Thu, 12/15/2022 - 18:09
Display Headline
To screen or not to screen: lung and breast cancer
Although the incidence of lung cancer in the United States has been falling in recent years because of a decrease in cigarette smoking, the disease is still the third most common cancer, and the leading cause of cancer death. In March 2014, the US Preventive Services Task Force (USPSTF) updated its 2004 recommendations for lung cancer screening by commissioning a systematic evidence review of low-dose computed tomography (CT) by focusing on new evidence from randomized clinical trials published since 2004. In addition, a modeling study provided information about the optimum screening age, screening interval, and the risk-benefit ratio for screening.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 12(6)
Topics
Page Number
228-230
Legacy Keywords
lung cancer, breast cancer, computed tomography, CT scan, chest x-ray, mammogram,
Sections
Although the incidence of lung cancer in the United States has been falling in recent years because of a decrease in cigarette smoking, the disease is still the third most common cancer, and the leading cause of cancer death. In March 2014, the US Preventive Services Task Force (USPSTF) updated its 2004 recommendations for lung cancer screening by commissioning a systematic evidence review of low-dose computed tomography (CT) by focusing on new evidence from randomized clinical trials published since 2004. In addition, a modeling study provided information about the optimum screening age, screening interval, and the risk-benefit ratio for screening.
Click on the PDF icon at the top of this introduction to read the full article.
Although the incidence of lung cancer in the United States has been falling in recent years because of a decrease in cigarette smoking, the disease is still the third most common cancer, and the leading cause of cancer death. In March 2014, the US Preventive Services Task Force (USPSTF) updated its 2004 recommendations for lung cancer screening by commissioning a systematic evidence review of low-dose computed tomography (CT) by focusing on new evidence from randomized clinical trials published since 2004. In addition, a modeling study provided information about the optimum screening age, screening interval, and the risk-benefit ratio for screening.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 12(6)
Issue
The Journal of Community and Supportive Oncology - 12(6)
Page Number
228-230
Page Number
228-230
Topics
Article Type
Display Headline
To screen or not to screen: lung and breast cancer
Display Headline
To screen or not to screen: lung and breast cancer
Legacy Keywords
lung cancer, breast cancer, computed tomography, CT scan, chest x-ray, mammogram,
Legacy Keywords
lung cancer, breast cancer, computed tomography, CT scan, chest x-ray, mammogram,
Sections
Citation Override
JCSO 2014;12:228-230
Disallow All Ads
Alternative CME
Article PDF Media